製品名
Y-320, ≥98% (HPLC)
InChI
1S/C27H29ClN6O2/c1-19-25(18-30-34(19)24-5-2-21(28)3-6-24)27(35)31-22-4-7-26(20(16-22)17-29)33-10-8-23(9-11-33)32-12-14-36-15-13-32/h2-7,16,18,23H,8-15H2,1H3,(H,31,35)
InChI key
BWZNJVZTAWBIFG-UHFFFAOYSA-N
SMILES string
N#CC1=CC(NC(C2=C(C)N(C3=CC=C(C=C3)Cl)N=C2)=O)=CC=C1N4CCC(CC4)N5CCOCC5
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (Warmed)
storage temp.
-10 to -25°C
Quality Level
関連するカテゴリー
Biochem/physiol Actions
Orally active immune modulator that suppresses inflammatory cytokines production and blocks P-glycoprotein-mediated MDR in vitro and in vivo.
Y-320 is an orally active immune modulator that inhibits IL-15-stimulated (100 ng/mL) IL-17 production from T-cells (IC50 = 57.4 nM using human CD4 T-cells & hIL-15; IC50 = 25.7/52.4 nM using murine CD4/Th17 T-cells and mIL-15 plus 1 μ/mL mCXCL12 & 1 μg/mL anti-CD3ε mAb) and prevents type II collagen-induced arthritis (CIA) in mice in vivo (0.3 to 3 mg/kg via daily p.o.). Y-320 is a P-glycoprotein (P-gp) substrate and sensitizes MDR tumor cells to chemotherapy drugs in cultures (paclitaxel IC50 with/without 500 nM Y-320 = 0.21/1.15 μM/Bads-200, 16/153 nM/Bads-72 breast cancer cells) and in mice in vivo (0% vs. 78% tumor growth suppression by 15 mg/kg PTX without or with 15 mg/kg Y-320 i.v.).
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Deleterious substance
pdsc
SML3848-50MG: + SML3848-VAR: + SML3848-10MG: + SML3848-BULK:
jan
Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy
American Journal of Translational Research, 12(2), 551-562 (2020)
Hiroyuki Ushio et al.
Pharmaceuticals (Basel, Switzerland), 7(1), 1-17 (2013-12-25)
Interleukin (IL)-15 and IL-17 are thought to play an important role in the pathogenesis of rheumatoid arthritis (RA) because both pro-inflammatory cytokines are found in synovial fluid of RA patients. In this study, we examined the pharmacological profiles of Y-320
Sara Hosseini-Farahabadi et al.
PLoS biology, 19(5), e3001221-e3001221 (2021-05-04)
Premature termination codons (PTC) cause over 10% of genetic disease cases. Some aminoglycosides that bind to the ribosome decoding center can induce PTC readthrough and restore low levels of full-length functional proteins. However, concomitant inhibition of protein synthesis limits the
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)